Antibody-based therapeutics for chronic rhinosinusitis with nasal polyps.

Shama Shishodia, Nora Haloob, Claire Hopkins

Expert opinion on biological therapy 2024 Jun

filter terms:

Chronic rhinosinusitis with nasal polyps (CRSwNP) is a prevalent inflammatory condition with heterogenous underlying endotypes, the most common being type 2 mediated inflammation. Several biologics have been developed to target specific pro-inflammatory cytokines and their receptors with proven efficacy in both quantitative and qualitative outcomes in patients with severe uncontrolled disease. However, there is an ongoing debate on the role of biologics relative to conventional therapies for CRSwNP and their efficacy in patient subgroups with non-polyp type 2 disease. This review examines the evidence on the efficacy and safety of biologics in CRSwNP, recommendations for their use, and discusses the broader economic factors influencing their application in clinical practice. Emerging real-life data demonstrating the variable efficacy of the available biologics for patients with CRSwNP, coupled with the high cost compared to conventional therapies such as surgery, renders biologics to be considered as an add-on therapy in the majority of cases. However, ongoing research into increasing biologic dose intervals and novel therapies targeting alternative pathways may offer a more cost-effective and sustainable option in future.

Citation

Shama Shishodia, Nora Haloob, Claire Hopkins. Antibody-based therapeutics for chronic rhinosinusitis with nasal polyps. Expert opinion on biological therapy. 2024 Jun;24(6):491-502